The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings

20 Dec 2018 12:07

RNS Number : 1452L
Byotrol PLC
20 December 2018
 

 

20 December 2018

 

 

 

 

 

Byotrol plc

("Byotrol", the "Company" or the "Group")

 

Director Dealings

 

 

Byotrol plc, the AIM listed anti-microbial technology company, announces that on 20 December 2018, John Langlands, Non-Executive Chairman of the Company, and Dr Trevor Francis, Chief Technical Officer of the Company, purchased 2,400,000 and 1,559,312 ordinary shares of 0.25p each ("Ordinary Shares") respectively at a price of 1.535p and 1.6p per Ordinary Share, respectively (the "Purchases").

Following the Purchases, Mr. Langlands has an interest in 8,000,000 Ordinary Shares representing approximately 1.85 per cent. of the total voting rights of the Company and Dr Trevor Francis has an interest in 4,470,214 Ordinary Shares representing approximately 1.03 per cent. of the total voting rights of the Company.

 

 

 

Enquiries:

David Traynor - Chief Executive, Byotrol plc 01925 742 000

David Paton - Investor Relations 07714 190 474

 

 

finnCap Ltd 020 7220 0500(Nominated Adviser & Broker)

Geoff Nash/Kate Bannatyne- Corporate Finance

Richard Chambers - Corporate Broking

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

 

Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

 

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Langlands

2.

Reason for the Notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 2,400,000

Price - 1.535 pence

d)

Aggregated information:

See 4c) above

e)

Date of the transaction

20 December 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr Trevor Francis

2.

Reason for the Notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 1,559,312

Price - 1.6 pence

d)

Aggregated information:

See 4c) above

e)

Date of the transaction

20 December 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPGGPUPUPRGPU
Date   Source Headline
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas
27th Sep 20214:36 pmRNSPosting of Annual Report & Accounts/Notice of AGM
1st Sep 20217:00 amRNSInvestor Presentation
20th Aug 202110:01 amRNSHolding(s) in Company
19th Aug 20217:00 amRNSFinal Results
27th Jul 20217:00 amRNSNotice of Results
21st Jun 20217:00 amRNSAlcohol-free Hand Sanitisers Backed by TIGGR
28th Apr 20219:47 amRNSExercise of Options & Total Voting Rights
27th Apr 20217:00 amRNSHolding(s) in Company
22nd Apr 20212:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSTrading Update
16th Apr 20214:40 pmRNSHolding(s) in Company
26th Feb 20217:00 amRNSTest Protocol for Testing Anti-Viral Efficacy
21st Jan 202110:30 amRNSExercise of Options & Total Voting Rights
8th Jan 20219:36 amRNSCapital reduction
21st Dec 20208:26 amRNSHolding(s) in Company
7th Dec 20207:00 amRNSInterim Results
13th Nov 202011:30 amRNSResult of AGM
13th Nov 20207:00 amRNSAGM Statement
6th Nov 202011:27 amRNSAnnual General Meeting – update on arrangements
20th Oct 20201:42 pmRNSPosting of circular & notice of AGM
14th Oct 20204:30 pmRNSExercise of Options & Total Voting Rights
13th Oct 202011:09 amRNSPUBLICATION OF AUDITED RESULTS
25th Sep 20207:00 amRNSDirector Dealing
25th Sep 20207:00 amRNSInvestor Presentation
24th Sep 20207:00 amRNSPreliminary Results
7th Sep 20207:00 amRNSGrant Award
27th Aug 20208:07 amRNSHolding(s) in Company
20th Aug 20208:10 amRNSHolding(s) in Company
18th Aug 20205:01 pmRNSHolding(s) in Company
18th Aug 20204:42 pmRNSSecond Price Monitoring Extn
18th Aug 20204:36 pmRNSPrice Monitoring Extension
17th Aug 20209:05 amRNSSecond Price Monitoring Extn
17th Aug 20209:00 amRNSPrice Monitoring Extension
3rd Aug 20207:00 amRNSTrading Update
16th Jul 20202:40 pmRNSHolding(s) in Company
3rd Jul 20207:00 amRNSExercise of Options and Total Voting Rights
29th Jun 20204:29 pmRNSHolding(s) in Company
19th May 202012:08 pmRNSHolding(s) in Company
14th May 20207:00 amRNSLicense Agreements and Update on Trading
27th Apr 20207:30 amRNSTrading Update
22nd Apr 20204:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:36 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSHolding(s) in Company
6th Apr 202011:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.